Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - NaPro BioTherapeutics Inc (NasdaqNM:NPRO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Recent Events
Aug 14Earnings Announcement
Location
6304 Spine Road Unit A
Boulder, CO 80301
Phone: (303) 530-3891
Fax: (303) 530-1296
Email: naproir@naprobio.com
Employees (last reported count): 121
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 36%
·Over the last 6 months:
 · 19 insider sells; 252.0K shares
  (2.4% of insider shares)
·Institutional: 27% (43% of float)
(51 institutions)
·Net Inst. Buying: 752.0K shares (+8.90%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
NaPro BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production and licensing of complex natural product pharmaceuticals, as well as on the development and licensing of novel genetic technologies for applications in human therapeutics and diagnostics, pharmacogenomics and agribiotechnology. The Company's lead product is paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus, trees. In addition to its efforts with paclitaxel and genetics, the Company is working on several types of compounds that have displayed activity as anti-cancer agents. The Company is actively engaged in evaluating the in-licensing or purchase of potential new products and/or technologies, whether or not those products or technologies are derived from natural products.
More from Market Guide: Expanded Business Description

Financial Summary
NPRO is a natural product pharmaceutical company, focused on the development, manufacture and commercialization of paclitaxel, a naturally-occuring anti-cancer agent found in certain species of yew trees. For the six months ended 6/30/01, revenues increased 51% to $6.1 million. Net loss increased 13% to $9.8 million. Revenues reflect increased product sales. Higher loss suffered from increased research and technology spending.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Leonard Shaykin, 57
Chairman and CEO
$465K
Sterling Ainsworth, Ph.D., 61
Vice Chairman, Pres and CSO
475K
Gordon Link, Jr., 37
CFO, VP-Fin. and Pres, NaPro Genomics
304K
Patricia Pilia, Ph.D., 51
Sec., Treasurer, Exec. VP
371K
David Denny, 48
VP, Operations
279K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NPROAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$5.031
Recent Price$9.25 
52-Week High
on 29-June-2001
$12.25 
Beta0.44 
Daily Volume (3-month avg)105.2K
Daily Volume (10-day avg)78.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+23.3%
52-Week Change
relative to S&P500
+65.5%
Share-Related Items
Market Capitalization$260.9M
Shares Outstanding28.2M
Float18.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.56 
Earnings (ttm)-$0.68 
Earnings (mrq)-$0.28 
Sales (ttm)$0.40 
Cash (mrq)$0.82 
Valuation Ratios
Price/Book (mrq)16.52 
Price/EarningsN/A 
Price/Sales (ttm)23.35 
Income Statements
Sales (ttm)$10.2M
EBITDA (ttm)-$16.1M
Income available to common (ttm)-$17.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-51.23%
Return on Equity (ttm)-139.90%
Financial Strength
Current Ratio (mrq)4.38 
Debt/Equity (mrq)0.97 
Total Cash (mrq)$23.1M
Short Interest
As of 8-Aug-2001
Shares Short139.0K
Percent of Float0.8%
Shares Short
(Prior Month)
360.0K
Short Ratio2.78 
Daily Volume50.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.